[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuroendocrine-tumor-of-pancreas-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuroendocrine-tumor-of-pancreas-disorder":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100402489",false,"NCT04520932","Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Pancreatic Neuroendocrine Tumors","Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Low Grade Pancreatic Neuroendocrine Tumors of Less Than 2cm in Size","RFANET","Inclusion Criteria:\n\n* Pancreatic mass of less than 2cm on MRI, or CT scan if contraindicated by MRI;\n* Diagnosis of neuroendocrine tumor on biopsy under high echo-endoscopy (HEE) with Ki67\\\u003C3%,\n* Non-secretory lesion.\n* Homogeneous HEE contrast taking;\n* No positron emission tomography (PET) FDG binding to the pancreatic mass;\n* Lesion \\\u003C20mm on conventional imaging at 6 months monitoring;\n* Age 18 to 80 years inclusive;\n* Patient in good general condition, World Health Organization \\[0-1\\];\n* Signed consent to participate;\n* Affiliation to healthcare insurance system or beneficiary of this regimen.\n\nExclusion Criteria:\n\n* Pregnant or likely to become pregnant (without effective contraception) or breastfeeding ;\n* A person in an emergency situation or deprived of liberty or placed under the authority of a tutor.\n* Life expectancy \\\u003C 1 year;\n* Severe hemostasis disorders;\n* Pancreatic and\u002For biliary ductal dilation;\n* Lesion considered to be adjacent to the pancreatic duct and\u002For bile duct;\n* Node extension and\u002For metastatic disease;\n* Patient being managed for another malignant lesion which is progressive or under treatment.","ALL","18 Years","80 Years",{"count":20,"type":21},82,"ESTIMATED","INTERVENTIONAL",[24],"NA","Pancreatic radiofrequency ablation (RFA) could therefore be an alternative to the monitoring of pancreatic neuroendocrine tumors (PNETs) and more particularly nonfunctioning PNETs (NF-PNETs), which is costly and anxiety-inducing for patients. To date, only a few small studies have evaluated this treatment and the results are encouraging. It appears necessary to consider a large-scale study to ensure the efficacy and low morbidity of pancreatic RFA applied to PNETs.",[27,28],"Neuroendocrine Tumor of Pancreas (Disorder)","Neuroendocrine Tumor Grade 1",[30,31,32,33],"Radio Frequency treatment","Echoendoscopy","Ablation","Efficacy","RECRUITING","2025-05-23",{"date":37,"type":38},"2025-05-25","ACTUAL",{"date":40,"type":38},"2021-03-30",{"date":42,"type":21},"2031-04",{"name":44,"class":45},"Institut Paoli-Calmettes","OTHER",""]